Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 27;6(48):eabc8733. doi: 10.1126/sciadv.abc8733

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

PMC Copyright notice

Fig. 6 — (A) Schematic illustration of self-monitoring for inhibition of tumor angiogenesis by Ag₂S@Fe₂C-DSPE-PEG-iRGD after intraperitoneal injection of saline and bevacizumab. (B) Real-time NIR-II fluorescence images of 4T1 breast cancer–bearing mice after intraperitoneal injection of normal saline and bevacizumab by Ag₂S@Fe₂C-DSPE-PEG-iRGD. (C) Representative photograph for volume change of tumor after intraperitoneal injection of normal saline and bevacizumab in 20 days. Inset: Corresponding harvested 4T1 breast cancer after 20 days. Photo credit: Zhiyi Wang, Peking University, China. (D) CD31 immunohistochemical staining of harvested 4T1 breast cancer after 20 days. Error bars, means ± SD (n = 5).